Mark A. Samuels
Mr. Samuels is a proven entrepreneur, inventor and seasoned senior executive with a strong background in product development, commercialization and sales of medical devices. With over 20 years of experience in executive management and corporate governance for both public and privately held technology companies, including women’s health, he brings a broad range of experience in government and strategic partner funding, equity investment and IPO. Mark was previously CEO and co-founder of Guided Therapeutics (SpectRx) , where he guided the Company to a $180 million dollar valuation after a successful IPO. After 10 years of experience as a public company CEO, Mr. Samuels worked with various startups including LumaMed (breast cancer imaging) and Regeneration Matrix (nerve regeneration) before joining OBMedical in early 2016.
Mr. Samuels is a graduate of the Georgia Institute of Technology, where he earned a Bachelor of Science in Physics and a Master of Science. In addition, Mark holds numerous patents, has earned an Emmy for technical innovation and is a licensed pilot.
Neil R. Euliano, Ph.D.,
Chairman, Chief Technical Officer, and Co-Founder
Dr. Euliano is the President and founder of Convergent Engineering, a biomedical research and development firm in Gainesville, Florida. Prior to founding Convergent Engineering, he was Vice President of R&D of NeuroDimension, Inc., a neural network software company. Before that, he was a Systems Engineer at AT&T Bell Labs. He has spent the past 15 years leading teams developing medical devices and technology. He was the chief designer and manager of the FDA-cleared Philips Healthcare VentAssist team at Convergent that developed intelligent decision support software for ventilated patients. He holds over 22 US patents and has several more pending.
Dr. Euliano is a graduate of the University of Florida, where he earned a Bachelor of Science in Computer Science, a Masters of Science in Electrical Engineering, and a Doctorate in Signal Processing and Electrical Engineering.
Chief Financial Officer
Mr. Baumbach has over 35 years of senior financial and operational management experience, primarily in service and technology companies, including eight years as a CPA with Ernst & Young (with three years on E&Y’s national office accounting and auditing staff). Private company experience includes serving as a senior financial executive for companies ranging from $1 billion dollars to pre-revenue startups, including as CFO for several early stage technology ventures and medical device companies, as well as holding senior financial positions at other technology and service companies (Cox Enterprises, Norrell Health Care, Lynk-Systems). Fred has helped lead Silverpop, Brickstream through successful equity raises totaling more than $50 million dollars.
Vice President, Sales and Marketing
Mr. O’Connor has over 25 years experience in the recruitment, training, deployment and management of top flight sales teams in the medical environment, specifically urology and women’s health. Specializing in early stage growth, he has held VP and Director level sales and marketing positions in early stage medical device organizations characterized by rapid growth and profitability. He has managed teams as large as seventy and with gross annual revenue exceeding 60 million dollars. Mr. O’Connor has negotiated contracts with dozens of large IDN’s and GPO’s, and GSA.
Mr. O’Connor is a graduate of the University of South Florida, where he earned a Bachelor of Science in Marketing and a Masters in Business Administration in Strategic Management from Regis University in Denver, Co.
Scott Dresden, MD, FACOG
Dr. Dresden is currently a general partner in Dresden Capital. He is a board certified OB/GYN, having delivered over 7,000 babies during his career. He is the holder of 11 patents and was the winner of two Ingram Research Awards early in his career. He is also the founder of several companies.
Dr. Dresden is a graduate of the University of Florida, where he earned a Bachelor of Science in microbiology. In addition, he earned his Medical Degree from the University of South Florida.
James B. Stubbs, Ph.D.,
Dr. James B. Stubbs, Ph.D., served as Chief Executive Officer and President at OBMedical Company from September 21, 2015 to March 21, 2016. Dr. Stubbs is a Startup Catalyst at Advanced Technology Development Center. Dr. Stubbs served as the Chief Science Officer at Cianna Medical, Inc. He founded Radiation Dosimetry Systems of Oak Ridge, Inc. (RDS) and served as its President. He served as Chief Technology Officer of Proxima, where he expanded its IP portfolio via patent filings and acquisitions and performed technical due diligence on potential new technologies and competitive products. He also served as a Consultant to Proxima for a year. He was Founder and served as Chief Technology Officer and Director of Focal Therapeutics, Inc. He has co-authored 48 peer-reviewed scientific articles in the brachytherapy and radiopharmaceutical fields.
Dr. Stubbs is a graduate of the University of Virginia, where he earned a Masters of Science and Ph.D. in Nuclear Engineering and Medical Physics. In addition, he earned a Bachelor of Science in Nuclear Engineering from the University of Florida.
Mark A Samuels
Neil Euliano, Ph.D.
Scientific Advisory Board
Dr. Mary Lake Polan, MD FACOG, Chair Emeritus of the Department of OBGYN at Stanford University School of Medicine. Adjunct Professor Columbia University School of Medicine. Dr. Polan specializes in reproductive endocrinology and infertility and has published more than 150 articles, chapters, and books of research in this field.
Dr. Michael Belfort, MD FACOG, Gynecology Chair of the Department of Obstetrics Baylor College of Medicine (BCM) and Texas Children’s Hospitals in Houston, TX. Specialist in maternal-fetal medicine and fetal intervention.
Dr. Maurice Druzen, MD FACOG, Vice Chair, Stanford University School of Medicine, Palo Alto, CA. Specializes in maternal fetal medicine.
Paul E. Dryden, President of ProMedic, Inc., provides market assessments, regulatory approval strategies and process, 510(k), strategic partnerships and distributions, market research, clinical trial development, and other associated services to the medical device industry. He has been involved in preparation, submission and review of over 600 Premarket Notification 510(k)s since 1996.
Mr. Dryden is a graduate of Purdue University, where he earned his Bachelor of Science in Microbiology. In addition, he earned a Masters in Business Administration from Butler University.